Menu Search
Equities

Bioporto A/S

2P4:BER

Bioporto A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)0.237
  • Today's Change-0.001 / -0.63%
  • Shares traded--
  • 1 Year change-2.87%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 18:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in DKKIncome statement in DKKView more

Year on year Bioporto A/S grew revenues 6.87% from 28.97m to 30.96m while net income improved from a loss of 75.92m to a smaller loss of 56.33m.
Gross margin71.13%
Net profit margin-147.84%
Operating margin-165.36%
Return on assets-41.06%
Return on equity-53.82%
Return on investment-51.28%
More ▼

Cash flow in DKKView more

In 2023, cash reserves at Bioporto A/S fell by 15.39m. Cash Flow from Financing totalled 40.79m or 131.76% of revenues. In addition the company used 55.46m for operations while cash used for investing totalled 277.00k.
Cash flow per share-0.1322
Price/Cash flow per share--
Book value per share0.244
Tangible book value per share0.2432
More ▼

Balance sheet in DKKView more

Bioporto A/S appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio5.35
Quick ratio5.16
Total debt/total equity0.0546
Total debt/total capital0.0517
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.